Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

INSIGHT-After hep C cure, companies target next big liver disease market

Sun, 09th Nov 2014 13:00

By Bill Berkrot

NEW YORK, Nov 9 (Reuters) - Now that new medicines promiseto cure millions of hepatitis C patients in coming years,drugmakers including Gilead Sciences Inc are turning theirattention to other liver diseases, with a potential market thatcould rival the success of statins, which generated more than$30 billion a year in sales at their peak.

Several companies are working on treatments for hepatitis B,which can be controlled but not yet cured, and for fatty liverconditions caused by rising obesity, which without treatmentcould affect half of all Americans by 2030, according to theAmerican Liver Foundation (ALF). Some of the drugs will addressadvanced fibrosis and cirrhosis, which are the scarring thatvirtually all liver diseases cause without effective treatments.Each of these drugs, once approved, could reach annual sales ofas much as $10 billion, industry analysts said.

Most of the treatments are now in early Phase I or Phase IIclinical trials, with more informative interim data on severalexpected over the course of the next year.

Gilead, which was first to market with itshepatitis C cure Sovaldi late last year and has been racking upabout $3 billion in sales each quarter, is a solid bet to beamong the leaders in the next wave of liver therapies, expertssaid.

"The Gilead program is encouraging," said Dr. NagaChalasani, director of gastroenterology and hepatology atIndiana University Hospital in Indianapolis, who isparticipating in clinical trials of promising drugs from Gileadand others.

Drugmakers are working to address the fatty liver diseaseknown as NASH, or nonalcoholic steatohepatitis. Withouttreatment, NASH can progress to liver-destroying cirrhosis andpotentially cancer.

ALF estimates that non-alcoholic fatty liver disease,including NASH, affects up to 30 percent of people in the UnitedStates. It can be caused by bad diets and alcohol abuse, and hasalso been tied to diabetes.

"We have no treatment for that condition other than tell apatient they need to lose weight," said Dr. MauricioLisker-Melman, director of the hepatology program at WashingtonUniversity School of Medicine in St Louis.

Intercept Pharmaceuticals has attracted the mostattention. Just released final data from a mid-stage clinicaltrial showed its obeticholic acid halted NASH progression andimproved liver scarring in primarily moderately ill patients."For now, no one else has demonstrated an antifibrotic effect inthis population, and I believe we are ahead of the pack in thatsense," said Intercept Chief Executive Mark Pruzanski.

Intercept plans to begin a Phase III trial with at least1,000 more seriously ill patients next year.

Dr. Scott Friedman, dean for therapeutic discovery at Mt.Sinai Hospital in New York, who has worked with virtually allthe companies in the field, said most were first testing drugsin patients whose liver damage is not advanced.

"Gilead has sort of leapfrogged that," Friedman said,tackling more serious damage, as its simtuzumab targets fibroticscarring directly, rather than inflammation or other drivers ofdisease. Reversing cirrhosis and improving liver function is"the highest bar I can think of in this business, and it wouldbe spectacular," he said.

Gilead faces competition from several smaller companies withpromising drugs in development, including Intercept, France'sGenfit, Israel's Galmed, GalectinTherapeutics, Conatus Pharmaceuticals andRaptor Pharmaceuticals, specialists said.

Gilead's antibody simtuzumab blocks an enzyme called LOXL2that is directly involved in laying down bands of collagen thatform the scar tissue behind cirrhosis. The collagen bands, whichresult from a wide variety of assaults on the liver, includingalcohol and drug abuse, cross link haphazardly to destroy theliver's architecture and function.

Gilead expects to have a strong indication of whether itsdrug is working when one-year data from a two-year Phase IIstudy becomes available next year.

"We have a very active research program," said ManiSubramanian, head of liver disease clinical research at Gilead."We're targeting everything: metabolic issues, inflammation andfibrosis directly." He acknowledged challenges faced bydrugmakers trying to address more advanced liver disease: "It'sbeen a graveyard for drugs that try to reverse fibrosis,"Subramanian said.

NOT FOR FAINT OF HEART

Chalasani at Indiana University Hospital estimated there maybe 20 different drugs being tried by various drug companies thatseem to be good targets.

But betting on them is not for the faint of heart.Intercept's shares shot from about $72 to over $400 in a matterof days in January after it was announced the trial of its drugwould meet the intended goal. On the flip side, Galectin lostnearly two thirds of its value in July, when its NASH drug usinga different approach had a setback in a Phase I trial.

Conatus is first testing its drug, emricasan, in patientsfacing acute liver failure, which has a 50 percent mortalityrate in 28 days. Chief Executive Steven Mento said the goal wasto "rescue these patients and prevent catastrophic organfailure." The company plans to work its way back, testing onless severely ill patients. The drug targets inflammation andexcessive cell death seen as drivers of the disease.

Dr. David Bernstein, chief of hepatology at North ShoreUniversity Hospital in Manhasset, N.Y., called the Conatus drugexciting and the initial trial a sensible approach.

"There's limited downside because there's nothing else thatcan be done anyway," said Bernstein, who expects to be involvedin future emricasan trials. "If you can reverse cirrhosis, youreally will change the impact of liver disease worldwide."

Drugs that succeed in reversing cirrhosis "can be as big aclass as the class of statins," said Conatus's Mento, referringto cholesterol drugs, such as Pfizer's Lipitor, which alone atits peak had annual sales of about $13 billion.

Raptor, by contrast, is developing a drug for NASH inchildren, a growing problem that has left liver specialistsfearing an obese generation that could require liver transplantsin the prime of life.

Raptor is testing a drug already approved for use inchildren for an extremely rare kidney disease. "In terms ofsafety, it's well established," said Raptor President and CEOdesignate Julie Anne Smith. It is now engaged in a year-longmid-stage trial of 169 children whose NASH was confirmed byliver biopsy with data expected in the first half of next year.

Companies are waiting for the U.S. Food and DrugAdministration to outline what it will take to approve a NASHdrug. "The FDA is struggling with what constitutes a meaningfulimprovement with a patient," Gilead's Subramanian said.

Goals such as reducing fat buildup or modestly improvingfibrosis would likely be simpler and quicker to achieve, forexample, than avoiding need for liver transplants.

The FDA is working "to identify clinically meaningfulendpoints for NASH and related liver diseases to help guide drugdevelopment," it said in a statement.

The uncertainty from the FDA also creates risks forinvestors and has led some analysts to focus on other livertherapies. RBC Capital Markets analyst Michael Yee favorscompanies taking on hepatitis B, such as Arrowhead Research Corp, Canada's Tekmira Pharmaceuticals, Gilead andIsis Pharmaceuticals in partnership withGlaxoSmithKline. And one private company not to beignored, OnCore Biopharma, founded by former Pharmassetexecutives, including the inventor of Gilead's Sovaldi.

While finding a cure for hepatitis B will not be easy,trials would mirror those for hepatitis C, with a simple bloodtest yielding clear results in months rather than years. (Reporting by Bill Berkrot. Editing by Michele Gershberg andJohn Pickering)

More News
11 Jun 2024 14:31

Zantac litigation fears overdone at GSK, says Shore Capital

(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still appealing", according to Shore Capital, which kept a 'buy' rating on the stock.

Read more
11 Jun 2024 09:32

TOP NEWS: GSK takes first steps to appeal Zantac ruling in Delaware

(Alliance News) - GSK PLC on Tuesday said it has taken the first steps to seek appeal of a ruling by the Delaware Superior Court in regard to its discontinued heartburn drug Zantac.

Read more
11 Jun 2024 09:12

LONDON MARKET OPEN: FTSE 100 up; UK unemployment rises to 4.4%

(Alliance News) - Stock prices in London opened higher on Tuesday, after a difficult day for markets on Monday amid the EU election fallout.

Read more
11 Jun 2024 07:52

LONDON BRIEFING: FTSE 100 called up despite unemployment rise

(Alliance News) - The FTSE 100 in London was called to open higher on Tuesday, after data showed that unemployment in the UK unexpectedly rose.

Read more
11 Jun 2024 07:22

GSK launches appeal to recent Zantac ruling

(Sharecast News) - GSK has started the process of appealing a recent decision by the Delaware Superior Court regarding the ongoing Zantac, or ranitidine, litigation, it announced on Tuesday.

Read more
11 Jun 2024 00:32

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

June 10 (Reuters) -

Read more
10 Jun 2024 22:49

Latest trial over Zantac cancer claims called off as plaintiff drops case

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

Read more
10 Jun 2024 19:00

TOP NEWS: GSK welcomes dismissal of Zantac case in Illinois

(Alliance News) - GSK PLC on Monday welcomed the dismissal of a case in the US concerning the heartburn drug, Zantac, which was due to start on Monday.

Read more
10 Jun 2024 12:42

EU to secure 40 million avian flu vaccines for 15 countries - officials

BRUSSELS, June 10 (Reuters) - The EU will sign a contract on Tuesday to secure over 40 million doses of a preventative avian flu vaccine for 15 countries with the first shipments heading to Finland, EU officials said on Monday.

Read more
10 Jun 2024 08:39

GSK gets FDA approval for Arexvy vax in 50-59 year olds at risk of RSV

(Alliance News) - GSK PLC on Monday announced that the US Food & Drug Administration has approved an expanded age indication for its respiratory syncytial virus vaccine.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 07:17

GSK's Arexvy vaccine approved for wider age range

(Sharecast News) - US regulators have approved the use of GSK's Arexvy vaccine for a younger age group, the biopharma group announced on Monday.

Read more
7 Jun 2024 19:34

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
3 Jun 2024 17:20

European shares kick-off June on a high note in anticipation of ECB rate cut

GSK tumbles as Zantac lawsuits allowed to proceed

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.